ASR Vermogensbeheer N.V. Takes Position in Insulet Corporation (NASDAQ:PODD)

Key Points

• ASR Vermogensbeheer N.V. has acquired a new stake in Insulet Corporation (NASDAQ:PODD), purchasing 3,274 shares valued at approximately $860,000 in the 1st quarter.
• Wall Street analysts are optimistic about Insulet, with a consensus rating of "Moderate Buy" and an average target price of $330.71, supported by research reports from multiple firms.
• Insulet's recent quarterly earnings exceeded expectations, reporting $1.17 EPS against an estimate of $0.92, alongside a year-over-year revenue increase of 32.9%.

ASR Vermogensbeheer N.V. acquired a new stake in Insulet Corporation (NASDAQ:PODD - Free Report) in the 1st quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor acquired 3,274 shares of the medical instruments supplier's stock, valued at approximately $860,000.

Several other large investors also recently made changes to their positions in PODD. Bank of Nova Scotia lifted its holdings in Insulet by 18.2% during the 4th quarter. Bank of Nova Scotia now owns 7,982 shares of the medical instruments supplier's stock valued at $2,084,000 after purchasing an additional 1,231 shares during the last quarter. Treasurer of the State of North Carolina lifted its holdings in Insulet by 0.4% during the 4th quarter. Treasurer of the State of North Carolina now owns 31,537 shares of the medical instruments supplier's stock valued at $8,233,000 after purchasing an additional 140 shares during the last quarter. Qtron Investments LLC acquired a new stake in Insulet during the 4th quarter valued at $739,000. Townsquare Capital LLC lifted its holdings in Insulet by 9.7% during the 4th quarter. Townsquare Capital LLC now owns 17,102 shares of the medical instruments supplier's stock valued at $4,465,000 after purchasing an additional 1,515 shares during the last quarter. Finally, Optimize Financial Inc acquired a new stake in Insulet during the 4th quarter valued at $256,000.

Wall Street Analyst Weigh In

PODD has been the subject of several research reports. The Goldman Sachs Group initiated coverage on Insulet in a report on Friday, May 30th. They set a "buy" rating and a $380.00 price target for the company. Wall Street Zen raised Insulet from a "hold" rating to a "buy" rating in a report on Saturday. Wells Fargo & Company increased their price objective on Insulet from $330.00 to $350.00 and gave the stock an "overweight" rating in a research report on Friday. Canaccord Genuity Group increased their price objective on Insulet from $331.00 to $353.00 and gave the stock a "buy" rating in a research report on Friday. Finally, Morgan Stanley reiterated an "overweight" rating on shares of Insulet in a research report on Thursday. Two analysts have rated the stock with a hold rating and seventeen have given a buy rating to the company. Based on data from MarketBeat, Insulet presently has a consensus rating of "Moderate Buy" and an average target price of $330.71.

Insulet Stock Up 1.2%

Shares of NASDAQ PODD opened at $307.10 on Friday. The company has a debt-to-equity ratio of 0.64, a quick ratio of 3.63 and a current ratio of 2.26. Insulet Corporation has a 52 week low of $173.00 and a 52 week high of $329.33. The stock has a market capitalization of $21.61 billion, a P/E ratio of 93.34, a PEG ratio of 2.72 and a beta of 1.35. The stock's fifty day moving average is $299.12 and its 200 day moving average is $283.03.

Insulet (NASDAQ:PODD - Get Free Report) last issued its quarterly earnings results on Thursday, August 7th. The medical instruments supplier reported $1.17 EPS for the quarter, topping analysts' consensus estimates of $0.92 by $0.25. Insulet had a return on equity of 23.78% and a net margin of 10.01%. The company had revenue of $649.10 million for the quarter, compared to analysts' expectations of $612.31 million. During the same quarter last year, the business earned $0.55 earnings per share. Insulet's revenue was up 32.9% on a year-over-year basis. Sell-side analysts forecast that Insulet Corporation will post 3.92 earnings per share for the current fiscal year.

Insiders Place Their Bets

In related news, SVP John W. Kapples sold 5,278 shares of the firm's stock in a transaction dated Wednesday, May 14th. The stock was sold at an average price of $318.47, for a total value of $1,680,884.66. Following the sale, the senior vice president directly owned 23,180 shares of the company's stock, valued at $7,382,134.60. This trade represents a 18.55% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. 0.39% of the stock is owned by company insiders.

Insulet Company Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.